Evolving treatment landscape for early and advanced pancreatic cancer

Table 2 Summary of first line studies for advanced pancreatic cancer

First line treatment for metastatic disease
Study[41,49,63-67,71]	Treatment	Treatment group				Control group
ORR	PFS (mo)	OS (mo)	1 yr Survival	ORR	PFS (mo)	OS (mo)	1 yr Survival
Standard of care
Burris et al[41], 1997	Gemcitabine vs 5-FU/LV	-	9 wk	5.65	18.0%	-	4 wk	4.01	2.0%
Conroy et al[49], 2011	FOLFIRINOX vs Gemcitabine	31.6%	6.4	11.1	48.4%	9.4%	3.3	6.8	20.6%
Von Hoff et al[71], 2013	Nab-paclitaxel plus gemcitabine vs gemcitabine	23.0%	5.5	8.5	35.0%	7.0%	3.7	6.7	22.0%
Gemcitabine doublets
Berlin et al[63], 2002	Gemcitabine plus 5-FU vs gemcitabine	6.9%	3.4	6.7	-	5.6%	2.2	5.4	-
Herrmann et al[64], 2007	Gemcitabine plus capecitabine vs gemcitabine	10.0%	4.3	8.4	32.0%	7.8%	3.9	7.2	30.0%
Moore et al[66], 2007	Gemcitabine plus erlotinib vs gemcitabine	8.6%	3.8	6.2	23.0%	8.0%	3.6	5.9	17.0%
Philip et al[67], 2010	Gemcitabine plus cetuximab vs gemcitabine	12.0%	3.4	6.3	-	14.0%	3.0	5.9	-
Ueno et al[65], 2013	Gemcitabine plus S1 vs gemcitabine	29.3%	5.7	10.1	40.7%	13.3%	4.1	8.8	35.4%

5-FU: 5-flurouracil; LV: Leucovorin; DFS: Disease free survival; OS: Overall survival; ORR: Overall response rate.